ReviewPathology oncology research : POR2020
Grading Ductal Carcinoma In Situ (DCIS) of the Breast - What's Wrong with It?
Review in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pathological Diagnosis, Work-Up and Reporting of Breast Cancer 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Pooled it
- Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ.BJC reports · 2025Article
- [Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 5th Hungarian Consensus Conference on Breast Cancer].Magyar onkologia · 2025Article
- Mitigating overtreatment of ductal carcinoma in situ.Radiology advances · 2025Review
- Therapeutic Potential of Underexplored Phytoconstituents Targeting Molecular Pathways in Breast Cancer Subtypes.Mini reviews in medicinal chemistry · 2025Review
- Review
- Low-risk DCIS. What is it? Observe or excise?Virchows Archiv : an international journal of pathology · 2022Review
- Discriminating low-grade ductal carcinoma in situ (DCIS) from non-low-grade DCIS or DCIS upgraded to invasive carcinoma: effective texture features on ultrafast dynamic contrast-enhanced magnetic resonance imaging.Breast cancer (Tokyo, Japan) · 2021Article
- Which type of cancer is detected in breast screening programs? Review of the literature with focus on the most frequent histological features.Pathologica · 2021Review
- The effect of an e-learning module on grading variation of (pre)malignant breast lesions.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.Breast cancer research and treatment · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at its lower risk end might not need treatment, a hypothesis tested in several currently running randomized clinical trials. This review describes the heterogeneity of grading ductal carcinoma in situ (DCIS). First it considers differences between low and high grade DCIS, and then it looks at several grading schemes and highlights how different these are, not only in the features considered for defining a given grade but also in their wording of a given variable seen in the grade in question. Rather than being fully comprehensive, the review aims to illustrate the inconsistencies. Reproducibility studies on grading mostly suggestive of moderate agreement on DCIS differentiation are also illustrated. The need for a well structured, more uniform and widely accepted language for grading DCIS is urged to avoid misunderstanding based misclassifications and improper treatment selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.